Burning Rock Biotech (NASDAQ:BNR) on Thursday reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, showing modest top-line growth alongside significant margin expansion and cost discipline in its precision oncology testing business.
Full-year revenue increased 4.6% year over year to RMB539.6 million (US$77.2 million).
Fourth-quarter revenue totaled RMB126.3 million (US$18.1 million).
Gross margin for the full year rose to 74.7%, reflecting improved cost efficiencies in laboratory operations and a favorable mix of higher-margin central laboratory and in-hospital testing services.
Operating expenses declined 36.4% year over year, driven by targeted cost reductions across R&D, sales and marketing, and general administrative functions following strategic streamlining efforts.
Elsewhere, the company highlighted several key operational advancements during the period, including the grant of a U.S. Patent and Trademark Office patent for its ELSA-seq (Enrichment-based Library Sequencing for Allele-specific detection) technology, which enhances detection of low-frequency variants in liquid biopsy samples.
The China National Medical Products Administration (NMPA) Center for Medical Device Evaluation (CMDE) also accepted its OncoScreen BCMatch Tissue Kit for priority review, positioning the product for potential regulatory approval as a companion diagnostic in targeted cancer therapies.
Additionally, Burning Rock published a study on minimal residual disease (MRD) monitoring in colorectal cancer in the journal Annals of Surgery, demonstrating the clinical utility of its circulating tumor DNA-based assays in post-surgical surveillance.